Biologics Market by product type (Monoclonal Antibodies (MAbs), Hormones, Growth Factors, Fusion Proteins, Cytokines, Therapeutic Enzymes, Blood Factors and Anticoagulants, Vaccines, Blood and Blood Products, Allergenic extracts, Human Cells and Tissues, Proteins, Gene Therapies, Cellular Therapies, and Xenotransplantation Products), by Therapeutics (Oncology, Cardiovascular, Immunological Diseases, Infectious Diseases, and Metabolic Diseases), and by Source material (Humans, Avian Cell Culture, Yeast, Bacteria, Insects Cell Culture, and Transgenics) - Global Opportunity Analysis and Industry Forecast, 2020-2027.
|
LI_184260
|
Pages: NA
|
Mar 2020 |
1008 Views
|
|
|
|
Author(s) :
NA
|
Tables: NA
|
Charts: NA
|
Formats*:
|
|
Biologics are the genetically engineered proteins derived from human genes. These are composed of sugars, proteins or nucleic acids or complex combination of these substances. The biologic drugs are derived from a variety of natural sources such as humans, animals, or microorganisms. These drugs are widely used in the treatment of rheumatoid arthritis, anemia, cancer, and other diseases. The products offered by the global biologics market include vaccines, blood and blood components, allergenics, somatic cells gene therapy, tissues, and recombinant therapeutic proteins.
Rise in incidences of chronic diseases, loss of patent extensions of branded drugs, and the increased availability of advanced diagnostics is expected to boost the growth of biologics market. In addition, growth in technology for the production of biologics is projected to fuel the market growth. However, difficulty in manufacturing biologic drugs and the process involved in maintenance, which includes preventing from environmental contamination, maintaining refrigeration processes, and others hinder the market. The increase in demand for advanced diagnostics in treatment purposes and the loss of patent extensions of branded drugs provide opportunity for the growth of global biologics market.
The market is segmented based on product type, therapeutics, source of material, and geography. Based on product type, it is divided into monoclonal antibodies (MAbs), hormones, growth factors, fusion proteins, cytokines, therapeutic enzymes, blood factors and anticoagulants, vaccines, blood and blood products, allergenic extracts, human cells and tissues, proteins, gene therapies, cellular therapies, and xenotransplantation products. The market on the basis of therapeutics is classified into oncology, cardiovascular, immunological diseases, infectious diseases, and metabolic diseases. By source material, it is categorized into humans, avian cell culture, yeast, bacteria, insects cell culture, and transgenics. By geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The key players in the global biologics market include F. Hoffmann-La Roche AG, Sanofi, Eli Lilly & Company, GSK Biologicals SA, Becton, Dickinson & Company, AstraZeneca plc, Bayer AG, Pfizer Inc, Novartis AG, and Merck KGaA.
Key Benefits :
- The study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent investment pockets.
- It offers a quantitative analysis from 2017 to 2023, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
- Comprehensive analysis of all geographical regions is provided, which elucidates the prevailing opportunities.
- Key players are profiled and their strategies are analyzed thoroughly, which helps understand the competitive outlook of the market.
- Extensive analysis by product elucidates the use of biologics drugs for the treatment of rheumatoid arthritis and other chronic illnesses.
Biologics Market Key Segments:
By Product Type
- Monoclonal Antibodies (MAbs)
- Hormones
- Growth Factors
- Fusion Proteins
- Cytokines
- Therapeutic Enzymes
- Blood Factors and Anticoagulants
- Vaccines
- Blood and Blood Products
- Allergenic extracts
- Human Cells and Tissues
- Proteins
- Gene Therapies
- Cellular Therapies
- Xenotransplantation Products
By Therapeutics
- Oncology
- Cardiovascular
- Immunological Diseases
- Infectious Diseases
- Metabolic Diseases
By Source Material
- Humans
- Avian Cell Culture
- Yeast
- Bacteria
- Insects Cell Culture
- Transgenics
By Geography
- North America
- U.S.
- Canada
- Europe
- France
- Germany
- UK
- Italy
- Spain
- Asia- Pacific
- Japan
- China
- India
- Australia
- LAMEA
- Brazil
- South Africa
We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:
- Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
- Technologically sophisticated and reliable insights through well audited and veracious research methodology
- Sovereign research proceeds that present a tangible depiction of marketplace
With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.
Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, web-casts and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast
Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develops analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth and forecasts
Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:
- Chief executives and VPs of leading corporations specific to industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)
Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.
REQUEST TOC/SAMPLE
Purchase Full Report of
Biologics Market- Global Opportunity Analysis and Industry Forecast, 2020-2027.
- Online Only
-
$3,456$3,110 - Online cloud access only
- Restricted print, copy, paste & download
- Read only
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Data Pack
-
$3,840$3,456 - Restricted to one authorized user
- One print only
- Available in
Excel - Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Single User
-
$5,370$4,833 - Restricted to one authorized user
- One print only
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Five Users
-
$6,450$5,805 - Limited to five authorized users
- Print upto five copies
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
-
Enterprise
License/PDF -
$8,995$8,096 - Unlimited
within
company/enterprise - Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Library Membership
- $0.00
- Published Content
E-access - Company Profiles
E-access - Newly Added Content Access
- 10 PDF
Downloads - 5 Excel Data
Pack Downloads - 250 Company Profiles PDF Downloads
-
Start reading.
Buy Now
This title and over 12,000+ are available on the Avenue Library. Subscription @ $559 T&C*.
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
Why Allied Market Research?
Infallible Methodology
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
Analyst Support
For complete satisfaction
Customization
On-demand customization of scope of the report to exactly meet your needs
TARGETED MARKET VIEW
Targeted market view to provide pertinent information and save time of readers
Get fresh content delivered
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.